Thrombopoietin in patients with hepatoblastoma

Marked thrombocytosis (over 50 x 10(4)/mu l) is frequently seen in patients with hepatoblastoma, Thrombopoietin (TPO), c-mpl ligand, has recently been purified as the major physiological regulator of the thrombopoiesis and is mainly produced in the liver, Since it is possible that TPO participates in thrombocytosis and the tumor growth of this particular hepatic tumor, serum TPO levels in addition to interleukin 1 beta (IL-1 beta) and IL-6 levels were assessed in seven untreated patients by using a sandwich enzyme-linked immunosorbent assay. High serum TPO levels were observed in all of the examined patients. The level ranged from 3.15 to 11.02 (mean +/- standard deviation; 6.08 +/- 1.25) fmol/ml, IL-6 levels were also somewhat higher than normal, Platelet counts, however, appeared to correlate more with serum TPO levels (p = 0.1) than with IL-1 beta (p = 0.5) and IL-6 (p = 0.2) levels, Furthermore, using the reverse transcriptase polymerase chain reaction method, the expression of c-mpl mRNA was found in five of eight hepatoblastoma tissues as well as TPO mRNA in all eight tissues. These observations suggest that thrombocytosis in hepatoblastoma patients results from the production of cytokine members, including TPO, within tumor tissues, Additionally, it is possible that TPO might act as a type of autocrine and/or paracrine system for cellular growth in this tumor.